Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRNP | P04156 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.46 |
| ▸ | ESR1 | P03372 | 10/20 | 0.46 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.41 |
| ▸ | CYP27A1 | Q02318 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4856450 | 0.86 | PRNP (0.69) | PRNPESR2ESR1MPOSMN1; SMN2 | |
| SCHEMBL4849146 | 0.83 | ESR2 (0.65) | ESR2ESR1 | |
| SCHEMBL4852297 | 0.76 | ESR2 (0.59) | PRNPESR2ESR1MPOSMN1; SMN2 | |
| SCHEMBL629696 | 0.71 | SMN1; SMN2 (0.58) | PRNPMPOSMN1; SMN2CYP24A1CYP27A1 | |
| SCHEMBL4858819 | 0.71 | ESR2 (0.62) | PRNPESR2ESR1 | |
| SCHEMBL14339932 | 0.71 | ESR2 (0.71) | ESR2ESR1 | |
| SCHEMBL4859137 | 0.69 | ESR2 (0.81) | ESR2ESR1 | |
| SCHEMBL2418445 | 0.69 | ESR2 (0.72) | ESR2ESR1 | |
| SCHEMBL2418341 | 0.69 | ESR2 (0.57) | ESR2ESR1 | |
| SCHEMBL6861853 | 0.68 | ESR2 (0.56) | PRNPESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432284-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432284-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432284-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20060041003-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| EP-1551820-A2 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004026887-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041003-A1 | Estrogen receptor modulators | GPER1, ESR2, ESR1 | PRNP 1632/4885ESR2 2/4885ESR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.